MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'byetta'. Sat, 03 Sep 2011 02:09:08 +0100 http://www.medworm.com/index.php?rid=4829304&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FMFHc1WKmzjk%2F Since 2002, Amylin Pharmaceuticals has worked closely with Eli Lilly to develop and market diabetes meds. Specifically, the two drugmakers sell the twice-a-day Byetta med and have been laboring to win approval for Bydureon, a once-weekly injectable that is designed to supplant the older drug. But like many partnerships, suspicision and mistrust often emerge and so Amylin has just filed a lawsuit in federal court charging Lilly with anticompetitive activity and breaching their “strategic alliance.” Why? This past January, Lilly signed a deal with Boehringer Ingelheim to jointly develop and sell several diabetes compounds that are in mid- and late-stage development, including a Boehringer oral diabetes agent known as linagliptin (read here). This has not sat well with Amylin, whi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4829304 Mon, 16 May 2011 13:43:16 +0100 4829304 http://www.medworm.com/index.php?rid=4658622&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F15TOpFMeOlc%2F There is nothing quite like a jury of your peers. And over in the UK, Novo Nordisk management was slapped around quite a bit by the Association of the British Pharmaceutical Industry for breaching industry codes concerning various promotional efforts for its Victoza diabetes med. What did the drugmaker do wrong? There were two cases, actually. In the first one, Novo Nordisk promoted the med on a website and at a symposium before regulators issued approval. The ABPI appeals board called this a “serious matter” that “displayed a poor understanding of the requirements” of the industry’s own code. In fact, the board was not convinced the drugmaker “understood the seriousness of the matter,” especially given there was another instance involving the same... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4658622 Wed, 30 Mar 2011 14:18:33 +0100 4658622 http://www.medworm.com/index.php?rid=4575247&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F0Udf2nUwwkU%2F And so another working week will soon draw to a close. This, of course, means that the time has come to daydream about weekend plans. Our agenda is rather modest - we hope to do fun things with assorted short people, catch up on some sleep and read interesting documents about a big drugmaker (this can actually be relaxing). What about you? Will you cavort with a special someone? Run some errands? Make plans to escape somewhere? Whatever your fancy, be safe and enjoy. Meanwhile, here a few tidbits. See you soon… Merck Not Obligated To Accept Bid For Dutch Organon Unit (Dow Jones) Amgen Will Buy Pfizer Plant In Ireland (Bloomberg News) Arena Pharma Narrows Losses (Associated Press) Roche’s Accutane Caused Tragedy For An Actor (Bloomberg News) Dendreon Gets OK To Expand Provenge C... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4575247 Fri, 11 Mar 2011 12:37:29 +0100 4575247 http://www.medworm.com/index.php?rid=4545252&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FgKTyXRkHZp0%2F For those who wonder why drugmakers shy away from head-to-head studies, consider the plight of Amylin Pharmaceuticals, Eli Lilly and Alkermes. A newly released study shows their forthcoming Bydureon diabetes med - a once-weekly injectable that is designed to supplant the twice-a-day Byetta - failed to lower blood sugar as effectively as a rival drug, Novo Nordisk’s Victoza. The results are causing investors to pound Amylin stock - shares were down about 25 percent all morning - as some analysts now question the ability of the drugmakers to successfully win FDA approval for the med anytime soon. The agency, you may recall, last year requested more info on manufacturing and a risk mitigation plan. Meanwhile, Victoza has been available more than a year. The bottom line: Patients who too... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4545252 Thu, 03 Mar 2011 20:18:12 +0100 4545252 http://www.medworm.com/index.php?rid=4285353&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fj_8GX6iXEFk%2F The holiday weekend may be in the offing, but the Pharmalot corporate campus is still humming. And why not? The world has not stopped spinning, after all, and there is always something interesting going on. So while you prepare for a celebration or simply slow down the usual pace, here are a few items to help you along. Meanwhile, we pass along holiday greetings and hope everyone has a chance to catch up on some fun things and enjoy life. See you soon… Cephalon Names Kevin Buchi As CEO (statement) Lundbeck Alcoholism Pill May Be A Goldmine (Bloomberg News) Novartis To Build Vaccine Plant In North Carolina (Raleigh News & Observer) FDA Reviews Safety Of Human Growth Hormone Drugs (Reuters) Pfizer And Bristol Bloodthiners Beats Sanofi Drug In Study (Bloomberg News) Massachusetts Award... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4285353 Thu, 23 Dec 2010 12:54:53 +0100 4285353 http://www.medworm.com/index.php?rid=4086516&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FOaRufoPftmM%2F The surprising news released last night that the FDA has refused to approve the Bydureon diabetes drug - which involves a three-way partnership between Eli Lilly, Alkermes and Amylin Pharmaceutical - adds tremendous pressure on the big drugmaker to pursue some kind of deal to bolster its anemic pipeline. An acquistion would be the likeliest approach, but Lilly may be more vulnerable bait itself. The initial reaction among some Wall Street wags is that Lilly may want to take a stake in, if not acquire Amylin, given that so much has already been invested in Bydureon, which the FDA rejected over concerns that cardiac abnormalities (look here). The med, which is a once-weekly version of Byetta, was already delayed due to cancer risks (see this), but Lilly has a long-standing diabetes franchise... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4086516 Wed, 20 Oct 2010 13:10:40 +0100 4086516 http://www.medworm.com/index.php?rid=3542873&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fdtv4OBHXOuY%2F Once again, another working week will soon draw to a close. And so the weekend agenda calls for a smattering of activities - taking the Pharmalot mascot for a constitutional, bike riding with one of the short people and watching another on the lacrosse field. And you? Whatever you plan, we hope you have a good time. And of course, do not forget mom. Have a great time… FDA To Review Lilly’s Byetta In Six Months (Reuters) Lilly To Cut 200 Sales & Marketing Jobs (Indianapolis Star) InVentiv To Be Bought For $900M By Thomas Lee (Wall Street Journal) Bayer Wins FDA Approval For New Type Of Contraceptive (Bloomberg News) Genzyme Plans $2B Buyback, May Sell Units (Associated Press) Australia Agrees To $2B In Price Cuts (PharmaTimes) photo thx to tipiro on Flickr creative commons ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3542873 Fri, 07 May 2010 11:37:14 +0100 3542873 http://www.medworm.com/index.php?rid=3460396&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F9dOm2DDD8d0%2F This is not good news for Eli Lilly or its partner, Amylin Pharmaceuticals, which are counting on their once-weekly version of the Byetta diabetes treatment to become a much-needed blockbuster. A Jan. 25 memo written by an FDA official notes that data suggests the med appears to “give a similar signal” as cancers seen rat studies of Novo Nordisk’s competing Victoza. Victoza, you may recall, was approved in January after nearly a year’s delay over safety concerns. At the time, the agency noted that thyroid tumors may be common with all extended-release diabetes drugs in a group of meds known as GLP-1 analogs, which includes Byetta and Victoza. Last month, the FDA delayed approving the new Byetta and sought more info on labeling and a risk-management plan, although ne... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3460396 Mon, 12 Apr 2010 11:54:26 +0100 3460396 http://www.medworm.com/index.php?rid=3443933&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2010%2F04%2Fthe-jurys-still-out-on-victoza.html Novo Nordisk is well-known in the diabetes community for its insulins, Novolog and Levemir, used to treat mainly type 1 diabetes. But in the last year, Novo launched a new kind of injectable, a “first line of defense for people with type 2 diabetes” called Victoza (generic: liraglutide). It’s a glucagon-like peptide-1 (GLP-1) drug designed [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=3443933 Wed, 07 Apr 2010 13:00:37 +0100 3443933 http://www.medworm.com/index.php?rid=3350568&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FWd4iws7642I%2F A pleasant morning here on the Pharmalot corporate campus. After a recent spell of snow, spring appears to have finally bloomed. And that makes it a bit easier to cope with those mid-week deadlines and meetings, yes? So grab a cup of something stimulating and dig in for another day. Here are a few interesting items to help you on your way. Cheers, everyone… Abbott Bests Biogen With Bid For Facet Biotech (Bloomberg) Bristol-Myers’ CEO 2009 Pay Was Down 22 Percent (Associated Press) Sandoz Names Don DeGolyer To Heads US Ops (Chain Drug Review) Novartis Takes Option On Transgene Cancer Vaccine (Reuters) Lilly, Amylin Diabetes Drug Await FDA OK (The Wall Street Journal) Teva Pharmaceuticals Names Phillip Frost As Chairman (Associated Press) Coffee pix thx to chichcacha flickr creat... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3350568 Wed, 10 Mar 2010 12:24:03 +0100 3350568 http://www.medworm.com/index.php?rid=3172202&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F5x3gAtaxrKg%2F Earlier this week, the FDA posted warning letters on its site to four drugmakers - Lilly, Bayer, Amylin Pharmaceuticals and Cephalon - for making inaccurate or incomplete statements while promoting their drugs. Amylin, for instance, was tagged because its reps made remarks that Byetta can be used as a stand-alone therapy, which was before the drug received that approval. Bayer was chastised for suggesting its Mirena contraceptive women help would feel more romantic or intimate when, in fact, the side effects indicate the opposite may occur. A dosing card for Cephalon’s Treanda, which treats chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, minimized risk and a Lilly promotional piece for its Cymbalta antidepressant minimized risk and overstated efficacy. As The Pink She... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3172202 Thu, 14 Jan 2010 12:02:03 +0100 3172202 http://www.medworm.com/index.php?rid=3167331&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2Fpk9h4agW5EY%2F I had mentioned in a prior post that at the advice of my doctor I had begun taking Byetta to help control my Type2 Diabetes. I have just seen an FDA warning about Byetta causing Pancreatitis in 30 reported cases. So far, no deaths…but do I want to be the first? Byetta works great for controlling my type 2 diabetes. Made as a synthetic version of the Gila Monster’s saliva, it assists in the way that your stomach empties, causing a slower release of glucose into your system and it also stimulates the part of the brain which sends the signal of feeling full to your stomach. It has been shown that Byetta can cause modest weight loss in those who take it. Byetta is like an appetite suppressant and a diabetes medication all in one. To good to be true right? Right. The FDA released a... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=3167331 Wed, 13 Jan 2010 05:00:00 +0100 3167331 http://www.medworm.com/index.php?rid=3119062&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fys_xmHL3T3A%2F File this under sticking point. The agency wants Amylin Pharmaceuticals to run more studies of its Type 2 diabetes drug, which was approved two months ago as a stand-alone treatment, due to safety concerns over pancreatitis, according to an investor note issued yesterday by Citigroup analyst Yaron Werber. At the time of the Oct. 30 approval, Amylin indicated prescribing info would warn about pancreatitis in patients with severe kidney disease. You may recall the twice-daily injectable drug was linked to six deaths last year (see here), which hurt sales. However, the Amylin statement didn’t mention additional studies. Werber wrote that he obtained a copy of the FDA’s approval letter and the agency considers post-marketing reports of acute pancreatitis, acute renal failure and thyr... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3119062 Thu, 24 Dec 2009 13:10:33 +0100 3119062 http://www.medworm.com/index.php?rid=2963280&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2FfehidxUyrgI%2F There are many people with Type 2 Diabetes that currently utilize the drug Byetta marketed by Eli Lilly and Amylin. The active ingredient in Byetta is a synthetic version of a protein produced in the saliva of the Gila Monster. More than just help with diabetes, researchers have just released findings for another positive benefit Byetta offers…weight loss. At the annual American Diabetes Association conference this week, researchers presented the findings of a 3 year 200 person study that was conducted on Byetta. The findings showed that Byetta causes weight loss as well as control of diabetes. “Well, it’s weird. You have to wonder how you can go from Gila monster saliva to something that works in humans,” said Sandra Leal, a pharmacist and diabetes expert at El Ri... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2963280 Thu, 05 Nov 2009 00:14:53 +0100 2963280 http://www.medworm.com/index.php?rid=2950996&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLRtHKZAGaF8%2F Such a busy pharma world and so little time to keep up, yes? Like you, we always poke around for items of interest, and so we thought we would point out a few you may enjoy from the past week. Think of it as a little bit of catching up. Meanwhile, we hope your weekend is enjoyable and look forward to seeing you again tomorrow… Amylin Pharmaceuticals and Lilly announced Byetta was approved as a stand-alone med, along with diet and exercise, for type 2 diabetes. Until now, the drug was approved only for patients taking other common diabetes treatments. Tucked away in their statement, they disclosed safety warnings relating to pancreatitis risks and use by patients with severe kidney disease. Six patients taking Byetta died in August 2008 from pancreatitis, prompting an FDA safety alert. P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2950996 Sun, 01 Nov 2009 18:44:39 +0100 2950996 http://www.medworm.com/index.php?rid=2939560&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FBYncsQFTMXI%2F Rise and shine. Another day beckons. And this is a special one here on the Pharmalot corporate campus as the shortest of short people celebrates a birthday. An especially large cup of stimulation is in order…among other things. While we fuss, please enjoy these items and, of course, have a nice day… Mylan Earnings Hurt By Medicaid Settlement (Reuters) SciClone Cuts 17 Percent Of Workforce (BusinessNewsTrends) AstraZeneca Profit Rises On Swine Flu (Bloomberg News) Roche: New Diabetes Drug Surpasses Byetta (The Wall Street Journal) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2939560 Thu, 29 Oct 2009 12:01:02 +0100 2939560 http://www.medworm.com/index.php?rid=2931288&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FIGI9cu6imDI%2F Why? The report warns that Australia faces a diabetes “disaster,” and some experts say it could be seen as a marketing push to win public subsidies for a new medicine, The Australian reports. The report warns an estimated 1.6 million Australians will be diagnosed with type 2 diabetes by 2050, and the disease will cost the country $14 billion a year. Compiled by the National Centre for Social and Economic Modelling at the University of Canberra, the report says more than 270,000 heart bypass operations on type 2 diabetic patients by 2050, and patients will suffer more than 250,000 strokes and 750,000 kidney complications. A release detailing the findings said while the findings were “alarming”, they “confirm effective and broader measures implemented now will ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2931288 Tue, 27 Oct 2009 12:07:47 +0100 2931288 http://www.medworm.com/index.php?rid=2857556&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2FyPOwBwLvSLU%2F The BYETTA Let’s Talk Campaign Boston is kicking off at the New England Spring Flower Show. The Flower show is being held at the Bayside Expo Center from March 17-25. You can find BYETTA Let’s Talk Campaign located at booth numbers 470 and 570. You can visit the BYETTA Let’s Talk Campaign booths from 10am – 9pm on the days of the show to watch Chef Smith cook delicious, healthy meals, speak to Virginia Valentine or meet Nikki Kimbrough of Bally Total Fitness. In an earlier article titled Delta Burke is Battling Diabetes with the Let’s Talk Campaign I went into detail about Delta Burke currently battling her own Diabetes and her efforts to spread the word on a healthier lifestyle for diabetics. For those who suffer diabetes or for their caretakers in the Boston... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2857556 Fri, 02 Oct 2009 22:50:41 +0100 2857556 http://www.medworm.com/index.php?rid=2576821&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2009%2F07%2F50-diabetes-myths-and-the-truths-you-need-to-know.html It’s not every day that you pick up a diabetes book with an ice cream cone on the cover — or two, actually! (OK, one is squashed) But the new book by fellow Type 1 D-writer and advocate Riva Greenberg is something different in many ways. There are numerous books that aim to dispel myths about [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=2576821 Mon, 06 Jul 2009 13:00:32 +0100 2576821 http://www.medworm.com/index.php?rid=2571092&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F0Fak4XNSHew%2F We know that Type 2 Diabetes is directly linked to obesity but what researchers are now just finding out is that even a modest weight loss can help the health of Type 2 Diabetes sufferers…but what is considered modest and how can drugs like Byetta help? According to Look AHEAD, Action For Health In Diabetes, a modest weight loss would be considered about 8 percent of a person’s total body weight. If you were 260 pounds that would mean a loss of about 20 pounds. Very doable when implementing a diabetes friendly diet and increasing your activity level. Even my friend Sean says I should look into byetta and phentermine with my doctor. This modest weight loss in a person with Type 2 Diabetes shows huge benefits including better blood sugar control and less need for diabetes and bl... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2571092 Sat, 04 Jul 2009 12:19:29 +0100 2571092 http://www.medworm.com/index.php?rid=2553205&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2009%2F06%2Fdoes-lantus-cause-cancer.html Considering what I am about to write, I feel a little guilty about the post headline here. But these sensational headlines are just the point: the media is abuzz the last few days with the possibility that Lantus insulin “may be linked” to cancer. The rumors started late last week, when the media got wind that [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=2553205 Mon, 29 Jun 2009 05:32:49 +0100 2553205 http://www.medworm.com/index.php?rid=2469841&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2FptQTY0Vg0u4%2F The BYETTA Let’s Talk Campaign is making a stop at the Third Avenue Merchants Spring Expo in Manhattan. The BYETTA Let’s Talk Campaign will there on Sunday, April 29th from 11am - 6pm. Taking on the role of spokeswoman for the BYETTA Let’s Talk Campaign, Delta Burke has been battling her own diabetes and wants to share the importance of a healthier more active lifestyle. If you or someone you are caring for is battling diabetes and are in the New York area please stop by the BYETTA Let’s Talk Campaign’s booth where you can speak with Virgina Valentine, see Chef Smith cook some tasty and health meals and also talk to Nikki Kimbrough of Bally Total Fitness. Keep in mind when battling type 2 diabetes, knowledge is power. Related Posts BYETTA Let’s Tal... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2469841 Wed, 10 Jun 2009 10:02:20 +0100 2469841 http://www.medworm.com/index.php?rid=2448022&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F4fSOhxypyMs%2F Actress Delta Burke was diagnosed with type 2 diabetes at the age of 41. Her goal is to get people talking about better management of diabetes. She is achieving that goal by leading the BYETTA Let’s Talk Campaign. The BYETTA Let’s Talk Campaign has been designed towards teaching patients of type 2 diabetes the importance and benefits of leading a healthier, more active lifestyle. It also has a large focus on the role of medication in the management of diabetes. The BYETTA (exenatide) injection is the debut medication of a new class of drugs called incretin mimetics. This new class of drugs are for the treatment of type 2 diabetes. BYETTA has many of the same effects as human incretin hormone glucagon. BYETTA improves blood sugar after eating through multiple effects that work i... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2448022 Mon, 01 Jun 2009 08:50:30 +0100 2448022 http://www.medworm.com/index.php?rid=2442405&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2FNeTn1H0UrXU%2F 2 diabetes medications have helped some patients control their weight. Barbara Oster has had diabetes for 15 years, and her medication wasn’t working so well, reported WBAL-TV in Baltimore. “It just blows you up, makes you feel like you’re gaining all this weight,” she said. The Food and Drug Administration recently approved two new diabetes drugs — Byetta and Symlin — that studies have proved help patients control their illness and cut back their eating. “One of the lovely side effects of both drugs is people tend to lose weight,” said Dr. Paula Yutzy, a diabetes educator at Baltimore’s Mercy Medical Center. Byetta comes from the saliva of a scary-looking lizard — the Gila monster. The drugs mimic the effects of hormones, helpin... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2442405 Sat, 23 May 2009 08:06:53 +0100 2442405 http://www.medworm.com/index.php?rid=2405907&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2Fpk9h4agW5EY%2F I had mentioned in a prior post that at the advice of my doctor I had begun taking Byetta to help control my Type2 Diabetes. I have just seen an FDA warning about Byetta causing Pancreatitis in 30 reported cases. So far, no deaths…but do I want to be the first? Byetta works great for controlling my type 2 diabetes. Made as a synthetic version of the Gila Monster’s saliva, it assists in the way that your stomach empties, causing a slower release of glucose into your system and it also stimulates the part of the brain which sends the signal of feeling full to your stomach. It has been shown that Byetta can cause modest weight loss in those who take it. Byetta is like an appetite suppressant and a diabetes medication all in one. To good to be true right? Right. The FDA released a... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2405907 Thu, 14 May 2009 06:28:59 +0100 2405907 http://www.medworm.com/index.php?rid=2405908&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F8AVkkMAu3Mk%2F I have Type 2 Diabetes which, like a lot of people out there, I struggle to control. Along with diet and exercise I was taking Metformin as a way to control my blood sugar level. All of a sudden it wasn’t cutting it. What do you do when your current treatment no longer works? It’s real easy to overlook the warning signs that your blood sugar levels are not under control unless you stick to a very strict sugar level testing regimen. Like a lot of people, once my blood sugar levels were under control for a long period of time…I kind of slacked off with the frequency of testing my sugar levels. Complacency is a huge factor in the denial associated with diabetes. Unfortunately I fell into this trap. I didn’t start with regular blood sugar level testing again until I w... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2405908 Mon, 11 May 2009 06:17:16 +0100 2405908 http://www.medworm.com/index.php?rid=2382729&cid=t_105755_134_f&fid=35137&url=http%3A%2F%2Fdiabetesupdate.blogspot.com%2F2009%2F05%2Fnew-study-proves-conclusively-byetta.html A study published in this month's Diabetes Care is titled in a way that makes it sound like Byetta "improves beta cell function."But if you read even the abstract you will see that "improving beta cell function" is NOT the same as rejuvenating beta cells--the claim that the drug manufacturer has been making for Byetta ever since it was released. In fact, what this study proves is the exact opposite: . While Byetta causes more insulin to be secreted in people who are taking the drug, this effect ends as soon as the drug is discontinued.Here's the study: One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. A randomized, controlled trial Mathijs C. Bunck. Diabetes Care 32:762-768, 2009What they did here wa... Diabetes Update blogs http://www.medworm.com/rss/comments.php?id=2382729 Fri, 01 May 2009 14:20:00 +0100 2382729 http://www.medworm.com/index.php?rid=2021729&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F478500834%2F The agency now appears likely to extends its review of the injectable diabetes med, which Lilly and Amylin Pharmaceuticals want approved as a stand-alone treatment, into next year. The FDA, however, apparently did not request additional studies, but is reviewing prescribing info and wants safety language revised, according to a statement from the drugmakers. Byetta has caused all sorts of turmoil for Lilly and Amylin this year, thanks to reports of pancreatitis. A total of four deaths were reported this past summer (look here), and a subsequent slowdown in sales contributed to a 25 percent staff reduction last month (see here). Amylin and Lilly are also developing a long-acting version of Byetta known as exenatide LAR, although its fate is unclear due to Byetta’s safety concerns. An... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2021729 Mon, 08 Dec 2008 14:32:32 +0100 2021729 http://www.medworm.com/index.php?rid=2017849&cid=t_105755_134_f&fid=35137&url=http%3A%2F%2Fdiabetesupdate.blogspot.com%2F2008%2F12%2Fnew-info-on-how-to-use-byetta-for-mody.html Since I did so extremely well on Januvia, but had to stop taking it because of its ability to promote Melanoma by inhibiting an enzyme used to fight metatastic cells, I had hoped I could switch to Byetta. The kind of MODY I have is one that responds extremely well to beta cell stimulation by sulfs, to the point where a sulf is overwhelming even at tiny doses.Unfortunately, when I tried Byetta two years ago, it was also overwhelming--causing me to hypo and go into a strange and unnerving mental state. The dose on the pen is set so I couldn't cut it back. I figure that since the main market for Byetta is very large, very insulin resistant Type 2s, the "small" dose was probably similar to the the Type 2 "starter dose" of insulin that is large enough to nearly kill insulin-sensitive me. But re... Diabetes Update blogs http://www.medworm.com/rss/comments.php?id=2017849 Sat, 06 Dec 2008 14:37:00 +0100 2017849 http://www.medworm.com/index.php?rid=1947482&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F449006769%2F The 25 percent staff reduction, which follows sluggish sales of its flagship Byetta diabetes med, is designed to save more than $100 million next year. After the dust clear, Amylin will have 1,800 employees. You may recall that, last summer, there were six deaths among patients with pancreatitis who took their Byetta diabetes drug (back story). “The purpose of the reorganization is to really put us in a stronger position as a company to execute our business plan and become cash flow positive by 2010,” Amylin Pharmaceuticals ceo Daniel Bradbury says in a statement. The drugmaker vows to increase sales of Byetta and its Symlin med for Type 1 diabetes, and bring to market a once-a-week version of Byetta, called exenatide LAR. The FDA recently rejected study data that was meant to sho... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1947482 Tue, 11 Nov 2008 01:25:35 +0100 1947482 http://www.medworm.com/index.php?rid=1933423&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F442409558%2F That’s because FDA approval for its much-anticipated exenatide LAR diabetes drug could be delayed, according to a filing with the Securities and Exchange Commission. The agency rejected study data that was meant to show that exenatide LAR batches made by its partner, Alkermes, were equivalent to batches made at Amylin’s own facility in Ohio. The upshot is that, if Amylin has to conduct another study, it would likely delay plans for FDA approval by the middle of 2009. Amylin continuing discussions with the FDA. Not surprisingly, the disclosure hammered stocks for both companies, since exenatide is supposed to be the follow-up for Byetta. The bad news follows reports in August of six deaths in patients taking its Byetta diabetes med, although the deaths have not been directly lin... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1933423 Tue, 04 Nov 2008 19:18:19 +0100 1933423 http://www.medworm.com/index.php?rid=1933211&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F11%2Fthe-state-of-januvia-and-its-election-ties.html Again, Januvia is one of the most searched-for terms on this site — which is interesting, because it’s an oral drug for controlling Type 2 diabetes with which I have no personal experience.  But there’s a “perfect storm” surrounding Januvia that encapsulates many of the controversial themes running through diabetes care: Show Me the Money If you [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=1933211 Tue, 04 Nov 2008 17:06:47 +0100 1933211 http://www.medworm.com/index.php?rid=1917969&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F10%2Fmy-life-as-a-compliance-analyst-the-case-for-pharma-reps.html I met Alexis at the recent BDI luncheon for women with Type 1 diabetes. She seemed bubbly and smart, and I felt an instant connection.  When I discovered her job title was “Compliance Analyst,” I just had to hear more about that.  Turns out it’s not quite what you think, but fascinating nevertheless. A Guest Post [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=1917969 Wed, 29 Oct 2008 14:14:51 +0100 1917969 http://www.medworm.com/index.php?rid=1883335&cid=t_105755_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F10%2Finsulin-pen-needles-that-go-click.html Who here uses an insulin pen? Tired of having to screw the needles on and off?  You might be very interested a new product from Can-Am Care called ClickFine, precision Swiss-made pen needles with patented technology that lets you click them on and off instantly. What’s the big deal, you ask?  Well, I personally switched from [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=1883335 Thu, 16 Oct 2008 14:13:11 +0100 1883335 http://www.medworm.com/index.php?rid=1791608&cid=t_105755_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F09%2Fwill-byetta-bounce.html “Exenatide LAR is not only more convenient than Byetta and liraglutide, but it may be the most potent diabetic agent in terms of (blood glucose) reduction.”More (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1791608 Sun, 14 Sep 2008 13:53:00 +0100 1791608 http://www.medworm.com/index.php?rid=1782895&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F387776565%2F The troubled Byetta diabetes drug, which is marketed by Lilly and Amylin Pharmaceuticals, worked better than Merck’s Januvia in trials that measured blood sugar levels after meals in 61 patients who tried each drug for two weeks. Those taking Byetta had lower blood-sugar levels and ate less food than when they used Januvia, according to the drugmakers, which expect to release the company-sponsored study today at a meeting of the European Association for the Study of Diabetes in Rome. The results contrast with the dismal news released last month that six patients taking Byetta died of pancreatitis. Amylin maintained there was no evidence to link the drug to the deaths, but Wall Street and doctors have been wary (back story). “There has been some confusion in the marketplace ab... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1782895 Tue, 09 Sep 2008 15:55:49 +0100 1782895 http://www.medworm.com/index.php?rid=1739108&cid=t_105755_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F08%2Famylin-byetta-more-bad-news.html Story (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1739108 Wed, 27 Aug 2008 15:39:00 +0100 1739108 http://www.medworm.com/index.php?rid=1739273&cid=t_105755_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F08%2Fmore-exposure-of-trouble-at-fda.html No doubt, you have read about the brew ha ha over the type 2 diabetes medicine Byetta being linked to pancreatitis which lead to the death of a few (I believe around 6 cases at the last count, out of over a million prescriptions worldwide). In fact, last night at 5:00 PM, Amylin Pharmaceuticals and Eli Lilly and Company (who jointly market Byetta, known generically as exenatide) held a conference call intended to do damage control on the issue. Lilly, in particular, depends heavily on Amylin's Byetta to fuel its sagging diabetes business. The company continues to lose market share in insulin to rivals Novo Nordisk and Sanofi Aventis largely because Lilly is the only one of the big 3 insulin makers who offers only a rapid-acting insulin analogue, but in order to win business from insurers a... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1739273 Wed, 27 Aug 2008 12:50:00 +0100 1739273 http://www.medworm.com/index.php?rid=1734249&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F375570999%2F Lilly and Amylin Pharmaceuticals are saying there have been four deaths among patients with pancreatitis who took their Byetta diabetes drug, in addition to the two deaths reported last week by the FDA. Amylin says the four cases were not captured by the FDA, which received six reports of patients who developed hemorrhagic or necrotizing pancreatitis that required hospitalization. Two of those died. The additional four cases reported today did not involve patients with the necrotizing form of the disease, which affects 15 percent to 20 percent of patients with inflammation of the pancreas. “It appears the FDA focused on necrotizing and hemorrhagic pancreatitis, whereas these other four cases only had pancreatitis in their history,” Orville Kolterman, Amylin’s senior vice... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1734249 Tue, 26 Aug 2008 21:45:43 +0100 1734249 http://www.medworm.com/index.php?rid=1734254&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F375207000%2F The drugmaker has scheduled a teleconference call for 5 pm EST today about last week’s FDA advisory on Byetta, the diabetes med that is marketed with Amylin Pharmaceuticals. The agency found that deaths continue to be reported despite earlier government warnings. The latest - six new reports were received of patients developing a dangerous form of pancreatitis, with two actually dying. Participating in the call will be Don Therasse, Lilly’s vp of global patient safety, Dan Bradbury, Amylin’s ceo and president, and Orville Kolterman, Amylin’s senior vp of R&D. However, the direction the call will take was not disclosed, prompting Catherine Arnold of Credit Suisse to write in an investor note this morning that the move may cause apprehension among investors. Why? Bye... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1734254 Tue, 26 Aug 2008 13:14:22 +0100 1734254 http://www.medworm.com/index.php?rid=1720336&cid=t_105755_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F08%2Famylin-byetta-pain-in-gut.html Story (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1720336 Wed, 20 Aug 2008 12:31:00 +0100 1720336 http://www.medworm.com/index.php?rid=1717490&cid=t_105755_134_f&fid=36049&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FDiabetesNotes%2F%7E3%2FiAyCK9JP6Q8%2F A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly’s Byetta. So-called GLP-1 drugs like Byetta — and similar products being developed by firms including Novo Nordisk and Roche — are seen as a promising new way to fight the growing problem of diabetes, which is closely linked to obesity. This is the first I have heard of these concerns. Byetta is a drug used to treat type 2 diabetes and is also known to help persons shed a lot of pounds. I feared this when Byetta first appeared last year. I was concerned that Byetta would be abused as a weight loss drug, While there is no proof or claims that this is happening here, I do wonder what the exact situ... Diabetes Notes blogs http://www.medworm.com/rss/comments.php?id=1717490 Tue, 19 Aug 2008 23:37:30 +0100 1717490 http://www.medworm.com/index.php?rid=1714166&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F368372415%2F The FDA is working on a stronger label for the widely used diabetes drug, which is marketed by Lilly and Amylin Pharmaceuticals after deaths continue to be reported despite earlier government warnings. Six new new reports were received of patients developing a dangerous form of pancreatitis while taking Byetta. Two patients died and four were recovering, the Associated Press reports. The drugmakers said in a statement that patients taking Byetta have shown “very rare case reports of pancreatitis with complications or with a fatal outcome.” They added that diabetes patients are already at increased risk of pancreatitis compared with healthy patients. The FDA announcement updated an October alert about 30 reports of Byetta patients developing the ailment. Regulators stressed that... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1714166 Mon, 18 Aug 2008 19:27:55 +0100 1714166 http://www.medworm.com/index.php?rid=1675139&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F352692430%2F That’s the speculation now that Roche has made an offer for the chunk of Genentech not under its control and Bristol-Myers Squibb is trying the same thing with ImClone Systems. So now the betting is that Lilly would bid for Amylin, its partner for the Byetta diabetes drug and a long-acting release version that is being developd. “While two large pharma companies have now moved to acquire their commercial partners (in which they already held shares), it is now reasonable to wonder whether there will be a rash of such deals, and who will be next,” Deutsche Bank analyst Barbara Ryan writes in an investor note. “While it is certainly possible and plausible that Lilly would buy Amylin…our assessment is that it is unlikely to be a near-term event, if it were to happ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1675139 Fri, 01 Aug 2008 15:04:42 +0100 1675139 http://www.medworm.com/index.php?rid=1522441&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F312998691%2F The famed corporate raider recently bought $200 million worth of stock in Amylin Pharmaceuticals, which is one of Lilly’s most critical partners, and the move raises questions about whether Icahn plans to push Amylin for a shakeup or a takeover, and whether that would threaten Lilly’s interests in the Byetta diabetes drug, The Indianapolis Star writes. On the other hand, pressure from Icahn could create an opportunity for Lilly to buy out its partner and get full control of the diabetes med, which generated $650 million in sales last year. But some analysts say it could become a multibillion-dollar blockbuster if a new long-acting version in clinical trials wins approval. Recently released clinical data seemed to raise its prospects, the paper notes. Icahn has disclosed no plan... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1522441 Mon, 16 Jun 2008 12:37:45 +0100 1522441 http://www.medworm.com/index.php?rid=1512244&cid=t_105755_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F06%2Fuic-improves-islet-transplants-how-long.html This study is extremely promising and shows that we can achieve success with fewer islet cells, freeing patients from the need to check their insulin, even after 20 or 30 years of suffering from diabetes," Dr. Oberholzer said.What did they do differently from the widely-tested Edmonton Protocol? Six patients received the slightly-modified UIC protocol -- which was a combination of etanercept (an anti-inflammatory drug developed to treat rheumatoid arthritis) plus the inclusion of exenatide (a drug approved for use in type 2 diabetes, better known as BYETTA) -- in addition to the Edmonton regimen. The new procedure allowed patients to get off insulin with only a single transplant versus the two to four transplants that were needed using the older protocol, said Oberholzer.By comparison, the... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1512244 Thu, 12 Jun 2008 16:00:00 +0100 1512244 http://www.medworm.com/index.php?rid=1502737&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F308273085%2F There was an 8 percent drop on Friday after Novo Nordisk presented data showing its once-a-day experimental med outperformed Amylin’s twice-a-day, Byetta flagship. Now, Amylin sunk another 10 percent after Roche released data at the American Diabetes Association meeting that poses yet another threat to both Byetta and a longer-lasting, follow-up drug. Both the Novo and Roche drugs are “viable” candidates, according to Cowen analyst Phil Nadeau, the Associated Press writes. As a result, competition will increase in the GLP-1 class of diabetes meds that stimulate the release of insulin only when glucose levels become too high. They also lead to modest weight loss, which is seen as an advantage over drugs. But Jim Birchenough of Friedman Billings Ramsey issued an investor no... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1502737 Mon, 09 Jun 2008 20:17:26 +0100 1502737 http://www.medworm.com/index.php?rid=1072405&cid=t_105755_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F195737938%2Fdrug_warnings_and_withdrawls_f_1.html FiercePharma has compiled a list of the top 10 drugs to have who have had approval either withdrawn or been forced to add stronger warning labels, by the FDA, with respect to their pharmaceutical products.  The list is based on 2006 worldwide sales so ranking does not necessarily include the big new makers.1. Antidepressants - Various companies - "Black" box warning regarding increased risk of suicidal thoughts.2. Epogen/Aranesp - Amgen - "Black" box warning of heart and vascular risk at higher doses3. Zyprexa - Lilly - Warning of weight gain and metabolic problems4. Avandia - Glaxo - "Black" box warning of heart failure and heart attack5. Actos - Takeda - "Black" box warning of heart failure6. Provigil - Cephalon - Waning of Stevens-J... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1072405 Wed, 05 Dec 2007 20:00:41 +0100 1072405 http://www.medworm.com/index.php?rid=1072422&cid=t_105755_134_f&fid=35137&url=http%3A%2F%2Fdiabetesupdate.blogspot.com%2F2007%2F12%2Fbad-science-study-pulbished-as.html Study after study shows that Byetta is not the wonder drug that its manufacturer would like you to believe it is, but that doesn't keep the drug company from spinning the results of their disappointing studies.Here's the abstract of this new study which was preformed by researchers who were forced to disclose that they were funded by the makers of Byetta:Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes AgentsIt concludes "it is feasible to sustain glycemic control when substituting exenatide for insulin". But a closer look at the study finds that this is NOT at all what it really found.First of all, the researchers stacked the deck for Byetta by comparing Byetta with insulin used incorrectly. To ... Diabetes Update blogs http://www.medworm.com/rss/comments.php?id=1072422 Wed, 05 Dec 2007 15:19:00 +0100 1072422 http://www.medworm.com/index.php?rid=1068797&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F194961311%2F In case you missed it, this has been quite a year for high-profile safety news. And so FiercePharma has compiled a list for the cocktail set, who want to keep track of such things. These are the 10 biggest drugs that were withdrawn or were issued new warnings by the FDA this year. The drugs are ranked by 2006 worldwide sales, which explains why such headline grabbers as Bayer’s Trasylol doesn’t appear - sales were already tanking on bad news. 1. Antidepressants - Various companies 2. Epogen/Aranesp - Amgen 3. Zyprexa - Lilly 4. Avandia - Glaxo 5. Actos - Takeda 6. Provigil - Cephalon 7. Zelnorm - Novartis 8. Byetta - Amylin 9. Xolair - Genentech 10. Fentora - Cephalon Source: FiercePharma Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1068797 Tue, 04 Dec 2007 14:15:23 +0100 1068797 http://www.medworm.com/index.php?rid=971537&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F173598660%2F I had mentioned in a prior post that at the advice of my doctor I had begun taking Byetta to help control my Type2 Diabetes. I have just seen an FDA warning about Byetta causing Pancreatitis in 30 reported cases. So far, no deaths…but do I want to be the first? Byetta works great for controlling my type 2 diabetes. Made as a synthetic version of the Gila Monster’s saliva, it assists in the way that your stomach empties, causing a slower release of glucose into your system and it also stimulates the part of the brain which sends the signal of feeling full to your stomach. Continue Reading FDA Warning On Byetta - Is It Safe? (Source: Battle Diabetes Blog) Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=971537 Tue, 23 Oct 2007 00:19:32 +0100 971537 http://www.medworm.com/index.php?rid=959857&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F171582475%2F The drugmaker reports that quarterly profits rose 6 percent, and thanks a 47 percent gain in sales of the Cymbalta antidepressant and a 27 percent increase in sales of Cialis, the erectile dysfunction pill. In the past, Lilly didn’t capture all Cialis sales, because the med belong to Icos, but the drugmaker bought Icos earlier this year. As a result, net income increased to $926.3 million, or 85 cents a share, from $873.6 million, or 80 cents, a year earlier. Revenue rose 19 percent to $4.6 billion partner. Cymbalta sales, by the way, reached $513.2 million and Cialis notched $311.4 million in revenue. Lilly’s biggest seller, the Zyprexa antipsychotic, posted an 8 percent increase in sales to $1.17 billion, but that reflected a price increase earlier this year. (See complete re... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=959857 Thu, 18 Oct 2007 12:38:15 +0100 959857 http://www.medworm.com/index.php?rid=958914&cid=t_105755_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F171290396%2Ffda_warning_for_amylin_pharmacueticals_byette.html Amylin Pharmaceuticals Inc. ( NASDAQ:AMLN) and Eli Lilly & Co.'s (NYSE:LLY) Byetta will have a new warning on its packaging due to the fact that the drug has been linked to dangerous inflammation of the pancreas.The FDA stated that it has received 30 reports of patients on Byetta developed acute pancreatitis. Of the thirty patients, 27 were hospitalized and 22 improved after stopping treatment.The injectable drug is marketed by Amylin and ELi Lilly for patients with Type 2 diabetes and over 700.000 people worldwide have used the drug since it was launched mid-year 2005.Amylin and ELi Lilly announced that they would notify doctors of the new precaustions and will add new warnings to the label. It is already noted on the label that some patients may experience pancreatitis when ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=958914 Wed, 17 Oct 2007 20:15:48 +0100 958914 http://www.medworm.com/index.php?rid=957304&cid=t_105755_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2007%2F10%2Ffda-warns-of-risk-for-pancreatitis-with.html In a sign that the FDA does not want to see a repeat of the events that occurred regarding the type 2 diabetes drug Avandia requiring more label warnings due to risk of cardiovascular events associated with that drug, the U.S. Food and Drug Administration has called attention to something which appears to be a tiny risk associated with another type 2 diabetes drug, Byetta. The Avandia incident received widespread media attention and brought Congress to re-examine the FDA's review procedures.Yesterday, the FDA reported that the popular injectable medicine to treat type 2 diabetes, Byetta (known generically as exenatide), may be linked to cases of acute pancreatitis in some patients. Pancreatitis is an inflammation of the pancreas. Acute pancreatitis (the kind that was linked by the FDA to B... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=957304 Wed, 17 Oct 2007 14:00:00 +0100 957304 http://www.medworm.com/index.php?rid=956251&cid=t_105755_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F170795954%2F The agency reviewed 30 post-marketing reports of acute pancreatitis, which is an inflammation of the pancreas that can be fatal. After deciding an association is “suspected in some of these case,” the FDA has asked Amylin Pharmaceuticals, to revise the label. A spokeswoman for Lilly, which co-markets the diabetes med, tells Reuters the risk of pancreatitis was included in Byetta’s label late last year. “What you’re seeing today is a clarification of language to show that severe and persistent abdominal pain could be a sign of something serious like pancreatitis” and require medical attention, says Kindra Strupp. The pancreatitis cases were “rare”, she maintains, given that Byetta has been taken by 700,000 people worldwide since being approved... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=956251 Tue, 16 Oct 2007 19:53:25 +0100 956251 http://www.medworm.com/index.php?rid=796061&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F141796981%2F I have Type 2 Diabetes which, like a lot of people out there, I struggle to control. Along with diet and exercise I was taking Metformin as a way to control my blood sugar level. All of a sudden it wasn’t cutting it. What do you do when your current treatment no longer works? (more…) byetta, Diabetes Control, frequent urination, metformin, type 2 diabetesShare This (Source: Battle Diabetes Blog) Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=796061 Wed, 08 Aug 2007 00:08:53 +0100 796061 http://www.medworm.com/index.php?rid=729827&cid=t_105755_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F07%2F12%2Fbyetta-januvia-declared-safe-and-effective-for-now%2F Filed under: Type 2, Drugs, Research, Daily NewsDiabetes drugs Byetta and Januvia have been declared safe and effective...for now...by researchers from Boston's Tufts-New England Medical Center. Both medications effectively reduce blood sugar by around one percent or less. This compares with older drugs like metformin, which can cause a drop of as much as two percent. On the other hand, the newer drugs are popular (and this has received tons of publicity over the last year or two) because they don't routinely cause weight gain like the older drugs and, in fact, they can even promote weight loss.The Tufts announcement came with a caveat, however: these drugs have not been around long. This means their long-term safety is not known. As far as side effects go, one author of the study, Anastas... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=729827 Thu, 12 Jul 2007 04:00:00 +0100 729827 http://www.medworm.com/index.php?rid=716533&cid=t_105755_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F07%2F05%2Fhomeopathy-and-diabetes%2F Filed under: Type 1, Type 2, Childhood, Adult Onset, Lifestyle, Products, SupportI was excited to see my friend, Lissa Coffey, appearing on The Today Show this morning. Lissa is a PhD, a relationship expert and sociologist. Lissa shares her ancient wisdom and modern style through her site, Coffey Talk, and her newsletters. A recent newsletter addressed homeopathic medicine and I share with you how this applies to the treatment of diabetes. Homeopathic medicine is a natural pharmaceutical science developed in the early 1800s. It uses small doses of natural substances (animal, vegetable, and mineral) to stimulate the body's own defenses. Homeopathy is a word derived from the Greek words for similar and disease. It is medicine based on the law of similars that says a substance will help to he... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=716533 Thu, 05 Jul 2007 04:00:00 +0100 716533 http://www.medworm.com/index.php?rid=796069&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F130371354%2F We know that Type 2 Diabetes is directly linked to obesity but what researchers are now just finding out is that even a modest weight loss can help the health of Type 2 Diabetes sufferers…but what is considered modest and how can drugs like Byetta help? (more…) byetta, Diabetes Control, diabetes weight loss, type 2 diabetesShare This (Source: Battle Diabetes Blog) Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=796069 Wed, 04 Jul 2007 06:34:39 +0100 796069 http://www.medworm.com/index.php?rid=796070&cid=t_105755_134_f&fid=36012&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F128592721%2F There are many people with Type 2 Diabetes that currently utilize the drug Byetta marketed by Eli Lilly and Amylin. The active ingredient in Byetta is a synthetic version of a protein produced in the saliva of the Gila Monster. More than just help with diabetes, researchers have just released findings for another positive benefit Byetta offers…weight loss. (more…) byetta, gila monster, type 2 diabetes, type 2 diabetes, weight lossShare This (Source: Battle Diabetes Blog) Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=796070 Thu, 28 Jun 2007 06:17:54 +0100 796070 http://www.medworm.com/index.php?rid=696942&cid=t_105755_134_f&fid=35137&url=http%3A%2F%2Fdiabetesupdate.blogspot.com%2F2007%2F06%2Fstudy-really-proves-byetta-sucks-for.html If you read title, this study sounds like it proved that Byetta is great for people with Type 2 diabetes--and that's how the press is playing it. BYETTA(R) Study Showed Sustained Blood Glucose Control Over Three Years in People with Type 2 DiabetesBut read further and you'll see how sad the results of this study really were.Byetta Produced Dangerous Blood Sugar Levels in 70% of those taking it. The press release brags: "After three years of BYETTA treatment, 46 percent of study participants achieved the American Diabetes Association's recommended target A1C of 7 percent and 30 percentof participants achieved an A1C of 6.5 percent." [emphasis mine]This means that fully 7 out of 10 of those taking Byetta had blood sugars high enough to damage their organs for the full 3 years of the study.Th... Diabetes Update blogs http://www.medworm.com/rss/comments.php?id=696942 Tue, 26 Jun 2007 15:12:00 +0100 696942 http://www.medworm.com/index.php?rid=571478&cid=t_105755_134_f&fid=35137&url=http%3A%2F%2Fdiabetesupdate.blogspot.com%2F2007%2F04%2Fbyetta-januvia-and-insulin.html Since I posted my blog entries on Januvia, and the associated page on my site, "What They Don't Tell You About Diabetes" I've received a lot of email from people who would prefer to take Januvia rather than Byetta and want to know my opinion about which is best.My suspicion is that if you have found that you respond strongly to a relatively low dose of a sulfonylurea drug such as Amaryl or glipizide (the sulfonylurea drug found in Glucovance) you may respond strongly to Byetta and possibly Januvia, though everything I'm hearing suggests that far fewer people respond to Januvia than Byetta. If you have no response to these drugs, it may indicate that you've gone past the point where stimulating your beta cells with any drug is going to produce insulin because you no longer have enough funct... Diabetes Update blogs http://www.medworm.com/rss/comments.php?id=571478 Thu, 26 Apr 2007 13:17:00 +0100 571478 http://www.medworm.com/index.php?rid=528788&cid=t_105755_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2007%2F04%2Fannals-of-internal-medicine-shows.html The Annals of Internal Medicine just published a clinical trial that compared a new type of anti-diabetic drug, exenatide, (Byetta, from Eli Lilly & Co, and Amylin) an incretin mimetic, to placebo for patients already being treated for Type 2 diabetes. [Zinman B, Hoofwerf BJ, Garcia SD et al. The effect of adding exenatide to a thiazolidinedione in supoptimally controled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.] But by publishing it with an editorial that was appropriately critical of the study design and methods, and appropriately attuned to how commercial research sponsors, such as pharmaceutical companies, biotechnology companies, and device manufacturers, may manipulate how research is designed, carried out, analyzed, and reported to serve their vested in... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=528788 Sat, 07 Apr 2007 19:35:00 +0100 528788 http://www.medworm.com/index.php?rid=489984&cid=t_105755_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F03%2F21%2Fwhere-do-you-shop%2F Filed under: Type 1, Type 2, Childhood, Adult Onset, Lifestyle, Drugs, Research, ProductsScarborough Research, the leading local market research firm for identifying consumer and retail behaviors in the United States, took the liberty of compiling a list of the top local markets selling diabetic medications in the last 12 months. A dubious distinction it may be, these locations burn like a flame for the moths of diabetes product resellers. Knoxville, TN, Memphis, TN, and Columbus, OH round out the top 3 local markets for diabetes medication purchasers. The Scarborough analysis also finds that Walgreens is the number one national drug store brand among diabetes medication purchasers. More than 3.1 million, or 18%, of these consumers purchased prescription drugs at Walgreens during the past ... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=489984 Wed, 21 Mar 2007 04:00:00 +0100 489984